NCT01209325 · OUTCOME
Geometric Mean Titers for HPV 18
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males · Source last updated 2020-08-11
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- mMU/mL
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Baseline through 24 months
What was measured
Geometric mean concentration of antibodies for HPV 18 at each visit
Analysis population: Eligible participants who received at least one vaccination with evaluable serum assessments.
Groups in this outcome
HPV 18 Sero-negative at Baseline
Sero-negative for HPV 18 at baseline.
HPV 18 Sero-positive at Baseline
Sero-positive for HPV 18 at baseline
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 18 Sero-negative at Baseline | 104 |
|---|
| HPV 18 Sero-positive at Baseline | 39 |
|---|
Reported measurements
Baseline
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 18 Sero-negative at Baseline | 104 |
|---|
| HPV 18 Sero-positive at Baseline | 39 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 18 Sero-negative at Baseline | 0 | Not reported | 0 | 0 | Not reported |
|---|
| HPV 18 Sero-positive at Baseline | 41.3 | Not reported | 28.1 | 60.7 | Not reported |
|---|
Month 7
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 18 Sero-negative at Baseline | 94 |
|---|
| HPV 18 Sero-positive at Baseline | 33 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 18 Sero-negative at Baseline | 294.2 | Not reported | 232.8 | 371.8 | Not reported |
|---|
| HPV 18 Sero-positive at Baseline | 482.2 | Not reported | 351.9 | 660.7 | Not reported |
|---|
Month 12
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 18 Sero-negative at Baseline | 88 |
|---|
| HPV 18 Sero-positive at Baseline | 30 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 18 Sero-negative at Baseline | 63.1 | Not reported | 48.7 | 81.6 | Not reported |
|---|
| HPV 18 Sero-positive at Baseline | 214.6 | Not reported | 141.0 | 326.6 | Not reported |
|---|
Month 18
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 18 Sero-negative at Baseline | 82 |
|---|
| HPV 18 Sero-positive at Baseline | 29 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 18 Sero-negative at Baseline | 39.2 | Not reported | 29.7 | 51.7 | Not reported |
|---|
| HPV 18 Sero-positive at Baseline | 244.3 | Not reported | 158.0 | 377.5 | Not reported |
|---|
Month 24
Analysis denominator · Participants
| Group | Source count |
|---|
| HPV 18 Sero-negative at Baseline | 73 |
|---|
| HPV 18 Sero-positive at Baseline | 31 |
|---|
Values in mMU/mL · Interval/dispersion: 95% Confidence Interval| Group | Value | Spread | Lower | Upper | Comment |
|---|
| HPV 18 Sero-negative at Baseline | 39.0 | Not reported | 28.7 | 52.8 | Not reported |
|---|
| HPV 18 Sero-positive at Baseline | 161.9 | Not reported | 103.3 | 253.7 | Not reported |
|---|
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 0
- upper Limit
- 0
- value
- 0
- group Id
- OG001
- lower Limit
- 28.1
- upper Limit
- 60.7
- value
- 41.3
- denoms
- counts
- group Id
- OG000
- value
- 104
- group Id
- OG001
- value
- 39
- units
- Participants
- title
- Baseline
- categories
- measurements
- group Id
- OG000
- lower Limit
- 232.8
- upper Limit
- 371.8
- value
- 294.2
- group Id
- OG001
- lower Limit
- 351.9
- upper Limit
- 660.7
- value
- 482.2
- denoms
- counts
- group Id
- OG000
- value
- 94
- group Id
- OG001
- value
- 33
- units
- Participants
- title
- Month 7
- categories
- measurements
- group Id
- OG000
- lower Limit
- 48.7
- upper Limit
- 81.6
- value
- 63.1
- group Id
- OG001
- lower Limit
- 141.0
- upper Limit
- 326.6
- value
- 214.6
- denoms
- counts
- group Id
- OG000
- value
- 88
- group Id
- OG001
- value
- 30
- units
- Participants
- title
- Month 12
- categories
- measurements
- group Id
- OG000
- lower Limit
- 29.7
- upper Limit
- 51.7
- value
- 39.2
- group Id
- OG001
- lower Limit
- 158.0
- upper Limit
- 377.5
- value
- 244.3
- denoms
- counts
- group Id
- OG000
- value
- 82
- group Id
- OG001
- value
- 29
- units
- Participants
- title
- Month 18
- categories
- measurements
- group Id
- OG000
- lower Limit
- 28.7
- upper Limit
- 52.8
- value
- 39.0
- group Id
- OG001
- lower Limit
- 103.3
- upper Limit
- 253.7
- value
- 161.9
- denoms
- counts
- group Id
- OG000
- value
- 73
- group Id
- OG001
- value
- 31
- units
- Participants
- title
- Month 24
- denoms
- counts
- group Id
- OG000
- value
- 104
- group Id
- OG001
- value
- 39
- units
- Participants
- description
- Geometric mean concentration of antibodies for HPV 18 at each visit
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Sero-negative for HPV 18 at baseline.
- id
- OG000
- title
- HPV 18 Sero-negative at Baseline
- description
- Sero-positive for HPV 18 at baseline
- id
- OG001
- title
- HPV 18 Sero-positive at Baseline
- param Type
- GEOMETRIC_MEAN
- population Description
- Eligible participants who received at least one vaccination with evaluable serum assessments.
- reporting Status
- POSTED
- time Frame
- Baseline through 24 months
- title
- Geometric Mean Titers for HPV 18
- type
- SECONDARY
- unit Of Measure
- mMU/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle